mRNA 3210
Alternative Names: mRNA-3210Latest Information Update: 29 Oct 2024
At a glance
- Originator Moderna Therapeutics
- Class RNA
- Mechanism of Action Phenylalanine hydroxylase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Phenylketonuria
Most Recent Events
- 22 Oct 2024 ModernaTX withdrawn prior to enrolment Phase-I/II clinical trials in Phenylketonuria in USA (IV) as sponsor no longer intends to recruit to this study (NCT06147856)
- 01 Dec 2023 Moderna Therapeutics announces intention to launch mRNA 3210 in Phenylketonuria by 2028
- 28 Nov 2023 Moderna Therapeutics plans a phase I/II trial for Phenylketonuria in US (IV) in January 2024 (NCT06147856)